Embla Medical hf. (CPH:EMBLA)

Market Cap	12.73B -1.3%
Revenue (ttm)	6.44B +12.7%
Net Income	614.80M +28.5%
EPS	1.43 +27.2%
Shares Out	425.89M
PE Ratio	20.87
Forward PE	18.15
Dividend	n/a
Ex-Dividend Date	n/a

Volume	43,053
Open	29.40
Previous Close	29.45
Day's Range	29.30 - 30.00
52-Week Range	25.00 - 37.90
Beta	0.46
Analysts	Buy
Price Target	33.50 (+12.04%)
Earnings Date	Jul 21, 2026

About Embla Medical

Embla Medical hf., together with its subsidiaries, provides non-invasive orthopedic products in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. It operates through three segments: Prosthetics and Neuro Orthotics, Bracing and Supports, and Patient Care. The Prosthetics and Neuro Orthotics segment offers mechanical products, such as lower and upper limb loss or difference; and bionic products, such as microprocessor-controlled feet, knees, hands, fingers, and neuro orthotic joints. The Bracing and Supports segment provides os...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 1971
• Employees: 4,500
• Stock Exchange: Copenhagen Stock Exchange
• Ticker Symbol: EMBLA

Financial Performance

In 2025, Embla Medical's revenue was $928.69 million, an increase of 8.63% compared to the previous year's $854.89 million. Earnings were $83.34 million, an increase of 22.05%.

Financial numbers in USD

Analyst Summary

According to 5 analysts, the average rating for EMBLA stock is "Buy." The 12-month stock price target is kr 33.50, which is an increase of 12.04% from the latest price.

Price Target

kr 33.50

(12.04% upside)

Analyst Consensus: Buy

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Aug 11, 2026

Data Sources Report a data error